Atonarp, a Tokyo, Japan-based hi-tech molecular diagnostics company, raised $33m in Series C funding.
Backers included new investors Japan Post Investment Corporation, SBI Investment Co., Ltd, and Northwestern Mutual Future Ventures as well as current investors, INCJ, Ltd, Innovative Venture Fund Investment Limited Partnership, and a major medical equipment manufacturing company.
The company intends to use the funds to grow its balance sheet and support ongoing product prototyping and commercialization into the healthcare market.
Led by Prakash Murthy, Chief Executive Officer, Atonarp is advancing its quantitative & miniaturized process mass spectrometer AMS.
Since early 2014, the company has raised more than $61m in three rounds of equity financing to bring to market process monitoring and healthcare diagnostics through its AI-based platforms of mass spectrometry and optical spectroscopy.
The latter aims to deliver pain-free point-of-care blood testing with lab-quality accuracy but with real-time actionable data.